Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials.
Susan StienenPatrick RossignolAntónio BarrosNicolas GirerdBertram PittFaiez ZannadJoão Pedro FerreiraPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2019)
In patients who had a myocardial infarction, clinical factors used in combination and treatment with eplerenone were associated with a PIIINP decrease. Interestingly, higher randomization PIIINP levels might help in identifying patients more prone to have an "anti-fibrotic response" when treated with MRAs. Predictors of an antifibrotic response after MI complicated by HF. Several clinical factors and biomarkers predicted a PIIINP decrease after an MI complicated by HF. There was a significant interaction between baseline PIIINP levels and eplerenone treatment: patients with baseline PIIINP ≥ 3.6 mmol/L treated with eplerenone had the best response (PIIINP decrease).
Keyphrases
- heart failure
- acute myocardial infarction
- st elevation myocardial infarction
- newly diagnosed
- end stage renal disease
- systemic sclerosis
- ejection fraction
- coronary artery disease
- prognostic factors
- mesenchymal stem cells
- atrial fibrillation
- bone marrow
- acute coronary syndrome
- peritoneal dialysis
- cardiac resynchronization therapy